News
RADAR-CNS kicks off: an IMI-funded research program into e-health for brain disorders
A major new research program supported by the Innovative Medicines Initiative (IMI) launched on 26 April. The RADAR-CNS program will develop new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology. Lygature will co-lead the regulatory work package and provide the data integration platform.
Continuous remote assessment using smartphones and wearable devices provides a complete picture of a patient’s condition at a level of detail which was previously unachievable. Moreover, it could potentially allow treatment to begin before a patient’s health deteriorates, preventing the patient relapsing or becoming more ill before they seek treatment.
RADAR-CNS (Remote assessment of disease and relapse – Central Nervous System) will exploit the potential of wearable monitoring technologies to improve the lives of the millions of people worldwide. Such ‘predictive medicine’ solutions will be backed by scientific evidence and will meet regulatory standards. At the same time, the privacy and security of patients and their care-givers will be fully protected.
Read more on the website of RADAR-CNS or download the press release here.